BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,890,422 shares of the biotechnology company's stock after acquiring an additional 1,583,826 shares during the quarter. Vanguard Group Inc. owned about 10.57% of BioCryst Pharmaceuticals worth $164,616,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. The Manufacturers Life Insurance Company grew its holdings in BioCryst Pharmaceuticals by 40.7% in the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after purchasing an additional 86,571 shares during the period. Principal Financial Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after buying an additional 375,890 shares during the period. Teacher Retirement System of Texas grew its stake in shares of BioCryst Pharmaceuticals by 25.1% during the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock valued at $438,000 after buying an additional 11,711 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after buying an additional 91,998 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after buying an additional 127,708 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 6.4 %

NASDAQ:BCRX traded up $0.41 during trading hours on Friday, hitting $6.82. The stock had a trading volume of 3,113,466 shares, compared to its average volume of 2,805,137. The business has a 50 day simple moving average of $7.96 and a two-hundred day simple moving average of $7.74. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.50. The company has a market cap of $1.43 billion, a PE ratio of -11.18 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period last year, the firm posted $0.28 earnings per share. The company's quarterly revenue was up 40.8% on a year-over-year basis. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

BCRX has been the subject of several research analyst reports. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target for the company. Royal Bank of Canada reissued an "outperform" rating and set a $11.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday. Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, JMP Securities reissued a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.